- Home
- OTLY vs AURA Comparison
OTLY vs AURA Comparison
Compare OTLY & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLY | AURA |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.1M | 333.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OTLY | AURA |
|---|---|---|
| Price | $11.05 | $5.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $15.50 | ★ $20.20 |
| AVG Volume (30 Days) | 67.0K | ★ 206.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.91 | N/A |
| Revenue Next Year | $5.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.25 | $4.73 |
| 52 Week High | $18.84 | $7.73 |
Technical Indicators
Market Signals| Indicator | OTLY | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 47.43 |
| Support Level | $10.71 | $5.08 |
| Resistance Level | $12.58 | $6.11 |
| Average True Range (ATR) | 0.49 | 0.37 |
| MACD | -0.14 | -0.02 |
| Stochastic Oscillator | 15.17 | 44.85 |
Price Performance
Historical ComparisonAbout OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.